Covid-19: India allows emergency use of Merck's pill, two more vaccines

Molnupiravir will be manufactured in India by 13 companies for restricted use.



Reuters file
Reuters file

By Reuters

Published: Tue 28 Dec 2021, 8:55 AM

Last updated: Tue 28 Dec 2021, 10:36 AM

India gave emergency use authorisation (EUA) for Merck's Covid-19 pill molnupiravir, and Serum Institute of India's Covovax and Biological E's Corbevax coronavirus vaccines, the country's health minister said on Twitter.

Molnupiravir will be manufactured in India by 13 companies for restricted use under emergency situation for treatment of adult patients with Covid-19, Health Minister Mansukh Mandaviya said

Earlier this year, drugmakers Aurobindo Pharma, Cipla, Sun Pharmaceuticals and some others signed non-exclusive voluntary licensing agreements with Merck to manufacture and supply molnupiravir in India.

Last week, the US FDA issued an EUA to molnupiravir for the treatment of mild-to-moderate coronavirus disease in adults.

Media reports earlier in the day said the subject expert committee under the Central Drugs Standard Control Organisation recommended allowing EUA for molnupiravir, Covovax and Corbevax.

India is working on ramping up oxygen supplies and strengthening health infrastructure to contain a possible surge of Covid-19 cases due to the Omicron variant.

ALSO READ:

The country has administered 1.43 billion Covid-19 vaccine doses so far, with more than 839 million of all adults having received at least one dose.

India plans to start administering Covid-19 booster shots as a precautionary measure to healthcare and frontline workers from January 10 and will begin vaccinating those aged 15-18 from January 3.

Medical experts have said India needs to double down on its vaccine campaign and some states have imposed night curfews and other restriction as a precaution in the run up to New Year festivities to prevent a spike in infections and a repeat of summer 2021 when a devastating second wave of infections left tens of thousands dead.


More news from coronavirus